BACKGROUND: Long-term opioid prescribing for musculoskeletal pain is controversial due to uncertainty regarding effectiveness and safety. This study examined the risks of a range of adverse events in a large cohort of patients prescribed long-term opioids using the UK Clinical Practice Research Datalink. METHODS: Patients with musculoskeletal conditions starting a new long-term opioid episode (defined as ≥3 opioid prescriptions within 90 days) between 2002 and 2012 were included. Primary outcomes: major trauma and intentional overdose (any). SECONDARY OUTCOMES: addiction (any), falls, accidental poisoning, attempted suicide/self-harm, gastrointestinal pathology and bleeding, and iron deficiency anaemia. "Control" outcomes (unrelated to opioid use): incident eczema and psoriasis. RESULTS: A total of 98,140 new long-term opioids users (median age 61, 41% male) were followed for (median) 3.4 years. Major trauma risk increased from 285 per 10,000 person-years without long-term opioids to 369/10,000 for a long-term opioid episode (<20 mg MED), 382/10,000 (20-50 mg MED), and 424/10,000 (≥50 mg MED). Adjusted hazard ratios were 1.09 (95% CI; 1.04, 1.14 for <20 mg MED vs. not being in an episode of long-term prescribing), 1.24 (95% CI; 1.16, 1.32: 20-50 mg MED) and 1.34 (95% CI; 1.20, 1.50: ≥50 mg MED). Significant dose-dependent increases in the risk of overdose (any type), addiction, falls, accidental poisoning, gastrointestinal pathology, and iron deficiency anaemia were also found. CONCLUSIONS: Patients prescribed long-term opioids are vulnerable to dose-dependent serious adverse events. Opioid prescribing should be reviewed before long-term use becomes established, and periodically thereafter to ensure that patients are not being exposed to increased risk of harm, which is not balanced by therapeutic benefit. SIGNIFICANCE: Long-term opioid use is associated with serious adverse events such as major trauma, addiction and overdose. The risk increases with higher opioid doses. Opioid prescribing should be reviewed before long-term use becomes established, and periodically thereafter to assess ongoing effectiveness.
BACKGROUND: Long-term opioid prescribing for musculoskeletal pain is controversial due to uncertainty regarding effectiveness and safety. This study examined the risks of a range of adverse events in a large cohort of patients prescribed long-term opioids using the UK Clinical Practice Research Datalink. METHODS:Patients with musculoskeletal conditions starting a new long-term opioid episode (defined as ≥3 opioid prescriptions within 90 days) between 2002 and 2012 were included. Primary outcomes: major trauma and intentional overdose (any). SECONDARY OUTCOMES: addiction (any), falls, accidental poisoning, attempted suicide/self-harm, gastrointestinal pathology and bleeding, and iron deficiency anaemia. "Control" outcomes (unrelated to opioid use): incident eczema and psoriasis. RESULTS: A total of 98,140 new long-term opioids users (median age 61, 41% male) were followed for (median) 3.4 years. Major trauma risk increased from 285 per 10,000 person-years without long-term opioids to 369/10,000 for a long-term opioid episode (<20 mg MED), 382/10,000 (20-50 mg MED), and 424/10,000 (≥50 mg MED). Adjusted hazard ratios were 1.09 (95% CI; 1.04, 1.14 for <20 mg MED vs. not being in an episode of long-term prescribing), 1.24 (95% CI; 1.16, 1.32: 20-50 mg MED) and 1.34 (95% CI; 1.20, 1.50: ≥50 mg MED). Significant dose-dependent increases in the risk of overdose (any type), addiction, falls, accidental poisoning, gastrointestinal pathology, and iron deficiency anaemia were also found. CONCLUSIONS:Patients prescribed long-term opioids are vulnerable to dose-dependent serious adverse events. Opioid prescribing should be reviewed before long-term use becomes established, and periodically thereafter to ensure that patients are not being exposed to increased risk of harm, which is not balanced by therapeutic benefit. SIGNIFICANCE: Long-term opioid use is associated with serious adverse events such as major trauma, addiction and overdose. The risk increases with higher opioid doses. Opioid prescribing should be reviewed before long-term use becomes established, and periodically thereafter to assess ongoing effectiveness.
Authors: Katherine B Santosa; Yen-Ling Lai; Chad M Brummett; Jeremie D Oliver; Hsou-Mei Hu; Michael J Englesbe; Emilie M Blair; Jennifer F Waljee Journal: J Gen Intern Med Date: 2020-08-03 Impact factor: 5.128
Authors: Dan Lewer; Prianka Padmanathan; Muhammad Qummer Ul Arfeen; Spiros Denaxas; Harriet Forbes; Arturo Gonzalez-Izquierdo; Matt Hickman Journal: Wellcome Open Res Date: 2021-05-05
Authors: Joe Schofield; Deborah Steven; Rebecca Foster; Catriona Matheson; Alexander Baldacchino; Andrew McAuley; Tessa Parkes Journal: BMC Public Health Date: 2021-06-24 Impact factor: 3.295
Authors: Jacoline J van den Driest; Dieuwke Schiphof; Marcel de Wilde; Patrick J E Bindels; Johan van der Lei; Sita M A Bierma-Zeinstra Journal: Rheumatology (Oxford) Date: 2020-09-01 Impact factor: 7.580
Authors: Jakob M Burgstaller; Ulrike Held; Andri Signorell; Eva Blozik; Johann Steurer; Maria M Wertli Journal: PLoS One Date: 2020-09-14 Impact factor: 3.240
Authors: Shirley Musich; Shaohung S Wang; James A Schaeffer; Luke Slindee; Sandra Kraemer; Charlotte S Yeh Journal: Popul Health Manag Date: 2020-03-02 Impact factor: 2.459
Authors: Atefeh Noori; Anna Miroshnychenko; Yaadwinder Shergill; Vahid Ashoorion; Yasir Rehman; Rachel J Couban; D Norman Buckley; Lehana Thabane; Mohit Bhandari; Gordon H Guyatt; Thomas Agoritsas; Jason W Busse Journal: BMJ Open Date: 2021-07-28 Impact factor: 2.692